 

Active ingredient: Azithromycin 

 

Form/Route: Extended Release Suspension/Oral 

 

Recommended studies: 1 study 

 

Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 2 gm 

Subjects: Normal healthy males and females, general population 

Additional comments: As an option, due to the relatively long half-life, the firm may 

wish to conduct this study using a parallel design. As an additional option for either the 

crossover or parallel design, the firm may wish to truncate the AUC at 72 hours. 

______________________________________________________________________________ 

 

Analytes to measure: Azithromycin in plasma 

 

Bioequivalence based on (90% CI): Azithromycin 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 


